Critical Contrast: ProMIS Neurosciences (NASDAQ:PMN) vs. Bullfrog AI (NASDAQ:BFRG)

ProMIS Neurosciences (NASDAQ:PMN) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Risk & Volatility

ProMIS Neurosciences has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Valuation and Earnings

This table compares ProMIS Neurosciences and Bullfrog AI’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMIS Neurosciences	$10,000.00	3,604.49	-$13.21 million	($1.13)	-1.68
Bullfrog AI	$60,000.00	375.49	-$5.36 million	($0.89)	-3.22

Bullfrog AI has higher revenue and earnings than ProMIS Neurosciences. Bullfrog AI is trading at a lower price-to-earnings ratio than ProMIS Neurosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

50.1% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProMIS Neurosciences and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMIS Neurosciences	N/A	N/A	-141.23%
Bullfrog AI	N/A	-134.87%	-111.19%

Analyst Recommendations

This is a summary of current recommendations for ProMIS Neurosciences and Bullfrog AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMIS Neurosciences	0	0	2	0	3.00
Bullfrog AI	0	0	0	0	N/A

ProMIS Neurosciences presently has a consensus price target of $8.00, indicating a potential upside of 320.83%. Given ProMIS Neurosciences’ higher possible upside, research analysts clearly believe ProMIS Neurosciences is more favorable than Bullfrog AI.

Summary

ProMIS Neurosciences beats Bullfrog AI on 8 of the 12 factors compared between the two stocks.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.